Prognostic model for unresectable hepatocellular carcinoma treated with dual PD-1 and angiogenesis blockade therapy
Background and aims Dual programmed death 1 (PD-1) and angiogenesis blockade therapy is a frontline treatment for hepatocellular carcinoma (HCC). An accepted model for survival prediction and risk stratification in individual patients receiving this treatment is lacking. Aimed to develop a simple pr...
Main Authors: | Tao Zhang, Jing Zhang, Qiao Li, Ning Shi, Xiaoming Chen, Qing Gou, Jian He, Zhiqiang Mo, Ling Lv, Qicong Mai, Jingwu Xu, Jiayan Fang, Wenhang Zhuang, Haosheng Jin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/1/e008191.full |
Similar Items
-
Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma
by: Kai Yan, et al.
Published: (2023-03-01) -
Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
by: Jia M, et al.
Published: (2022-09-01) -
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
by: Tomoko Aoki, et al.
Published: (2020-10-01) -
Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
by: Xindan Kang, et al.
Published: (2023-08-01) -
Practicality and potential restrictions of unresectable hepatocellular carcinoma prognostic index
by: Coskun Ozer Demirtas, et al.
Published: (2022-12-01)